GlassScriptPhysician profile
Matthew P Shupe
NPI 1629206750
$2,546.56
in general payments reported to CMS, 2019-2025
36 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $236 · 2021: $40.52 · 2022: $364 · 2023: $322 · 2024: $222 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $332.81 | 2020-2023 | Tukysa, Padcev, Adcetris |
| Merck Sharp & Dohme LLC | $322.18 | 2019-2025 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $259.78 | 2019-2025 | Opdualag |
| Abbvie INC. | $257.28 | 2019-2024 | |
| Pfizer INC. | $159.24 | 2023-2025 | |
| Genzyme Corporation | $156.83 | 2019-2025 | |
| Daiichi Sankyo INC. | $123.77 | 2019-2023 | Enhertu |
| Eisai INC. | $106.77 | 2020-2025 | |
| Exelixis INC. | $72.17 | 2019 | |
| Genentech USA, INC. | $68.55 | 2019-2025 | Polivy, Lunsumio, Perjeta |
| Karyopharm Therapeutics INC. | $62.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $61.50 | 2019-2025 | Imfinzi |
| Clovis Oncology, INC. | $51.45 | 2019-2022 | |
| Celgene Corporation | $46.92 | 2020-2023 | Opdualag, Pomalyst |
| Ipsen Biopharmaceuticals, INC | $41.64 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $39.38 | 2019 | |
| Mirati Therapeutics, INC. | $36.99 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $31.02 | 2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $26.90 | 2019-2022 | |
| Array Biopharma INC | $24.92 | 2023 | Lorbrena, Braftovi, Mektovi |
| Kite Pharma, INC. | $23.55 | 2025 | Yescarta |
| Teva Pharmaceuticals USA, INC. | $21.06 | 2019 | |
| Astellas Pharma US INC | $19.93 | 2023 | Xospata |
| Emd Serono, INC. | $19.16 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.26 | 2025 | |
| Adaptive Biotechnologies Corporation | $18.18 | 2022 | |
| Blueprint Medicines Corporation | $18.05 | 2023 | Ayvakit |
| Glaxosmithkline, LLC. | $16.47 | 2025 | Jemperli, Zejula |
| Janssen Biotech, INC. | $15.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.62 | 2024 | Hyqvia |
| Taiho Oncology, INC. | $13.90 | 2019 | |
| Kyowa Kirin, INC. | $13.74 | 2022 | |
| Agios Pharmaceuticals, INC. | $13.55 | 2023 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2019 | |
| Gilead Sciences, INC. | $12.93 | 2019 | |
| Incyte Corporation | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Shupe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.